Pharmaceuticals

Viridian Therapeutics: A Biotech Tapping High-Growth Potential

See how Viridian Therapeutics (NASDAQ: VRDN) is innovating thyroid eye disease treatments with advanced therapies and a growing market opportunity.

Billion-Dollar Market Potential for Targeted Cancer Therapies

Radiopharmaceuticals are revolutionizing cancer treatment, attracting billions in investments. Discover the potential and challenges for investors in this emerging market.

Roche Shares Tumble After Obesity Drug Data

Roche's stock dropped 4.5% due to gastrointestinal side effects from its obesity drug CT-388, raising concerns among investors about the drug's future.

Rising GLP-1 Medication Use to Drive Employer Healthcare Costs

Discover the financial impact of rising GLP-1 medication usage on employer healthcare costs and its relevance for retail investors.

Johnson & Johnson Proposes $6.48 Billion Settlement for Talc Lawsuits

Discover why Johnson & Johnson's $6.48 billion talc settlement matters for retail investors: stock impact, legal risks, governance insights, financial health, and industry precedent.

CARGO Therapeutics Inc (NASDAQ: CRGX) Q2 Results

CARGO Therapeutics reported Q2 2024 results with a slight EPS miss and higher-than-expected R&D expenses, while maintaining a strong cash position.

Novo Nordisk Stock Drops on Profit Forecast Revision

Novo Nordisk faces stock drop and competition pressures. Revenue growth vs. profit forecast. Political scrutiny and market strategy in focus.

Eli Lilly's Zepbound Shows Promise in Heart Failure Patients

Eli Lilly's Zepbound & Novo Nordisk's Wegovy show health benefits beyond weight loss, influencing investment strategies in pharmaceutical stocks.

Viking Therapeutics Accelerates Weight Loss Drug Development

Viking Therapeutics' fast-tracked weight loss injection could reshape the market, impacting investors' portfolios and strategies.

Embecta Considers Sale Amid Struggles

Embecta Corp, the top insulin pen needle producer, eyes a sale after a 70% share price drop post-spin-off.

SRPT Stock: Sarepta's Elevidys Gets Green Light for Duchenne Patients

Sarepta Therapeutics Inc (NASDAQ: SRPT) achieves FDA approval for its gene therapy for Duchenne muscular dystrophy in patients aged four and older.

CanaQuest Bolsters Team for CQ-001 Trials

CanaQuest Medical (OTC: CANQF) adds experts to advance CQ-001 through clinical trials for FDA approval in epilepsy.

Sign-Ups For Novo Nordisk's Weight Loss Drug Soar In US

Novo Nordisk's weight loss drug Wegovy experiences booming sign-ups in the US, while facing pricing pressures and emerging competition.

Biogen Tops Q1 Estimates with Alzheimer's Boost

Dive into Biogen's impressive Q1 earnings, featuring an EPS beat and significant LEQEMBI sales growth. Explore what these results mean for the company's 2024 outlook.

Johnson & Johnson (JNJ) Acquires Shockwave Medical (SWAV) for $13.1B

J&J acquires Shockwave Medical for $13.1B, bolstering its medical device portfolio and positioning retail investors for potential growth in the cardiovascular technology sector.